On July 7, 2025, Quanterix Corporation announced the completion of its previously announced acquisition of Akoya Biosciences, Inc. This transaction establishes a scaled leader in the early detection of disease for the neurology, oncology, and immunology markets.
Under the amended merger agreement, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash to Akoya shareholders. This acquisition is expected to expand Quanterix's served addressable market from $1 billion to $5 billion.
Masoud Toloue and Vandana Sriram will continue as CEO and CFO of the combined company. Additionally, Scott Mendel and Myla Lai-Goldman, MD, designated by Akoya, joined the Quanterix Board of Directors. At closing, Quanterix had approximately $163 million in cash after repaying Akoya’s debt and transaction-related costs, with the combined business expecting an accelerated path to profitability by 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.